B02BD02 • coagulation factor VIII • Blood and blood forming organs | Vitamin k and other hemostatics | Blood coagulation factors
Coagulation factor VIII is an essential protein for the blood clotting process, playing a key role in forming the clot that stops bleeding. A deficiency of factor VIII causes hemophilia A, a hereditary disease characterized by spontaneous or prolonged bleeding. Treatment with factor VIII is vital for preventing and controlling these bleeding episodes.
Factor VIII is administered intravenously under medical supervision, with the dose determined by the severity of the deficiency and the type of bleeding. Treatment can be given prophylactically or as needed, for example during surgeries or after injuries.
Side effects may include allergic reactions, fever, headaches, or, rarely, the development of antibodies that can reduce the effectiveness of the treatment. Careful monitoring of the patient is essential to quickly detect any adverse reactions and adjust the treatment if necessary.
Therapy with factor VIII has significantly improved the quality of life for people with hemophilia A. Following medical advice and being informed about possible risks contribute to safe and effective treatment.
Substance: coagulation factor VIII
Date of last drug list: 01-07-2013
Commercial code: W42209001
Concentration: 250UI
Pharmaceutical form: lyophilizate+solvent for injection
Quantity: 1
Product type: generic
Prescription restrictions: S - Medicines prescription reserved for use in certain specialized fields.